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An allelic variant in the intergenic 
region between ERAP1 and 
ERAP2 correlates with an inverse 
expression of the two genes
Fabiana Paladini1, Maria Teresa Fiorillo1, Carolina Vitulano1, Valentina Tedeschi1, 
Matteo Piga2, Alberto Cauli2, Alessandro Mathieu2 & Rosa Sorrentino1
The Endoplasmatic Reticulum Aminopeptidases ERAP1 and ERAP2 are implicated in a variety of 
immune and non-immune functions. Most studies however have focused on their role in shaping the 
HLA class I peptidome by trimming peptides to the optimal size. Genome Wide Association Studies 
highlighted non-synonymous polymorphisms in their coding regions as associated with several immune 
mediated diseases. The two genes lie contiguous and oppositely oriented on the 5q15 chromosomal 
region. Very little is known about the transcriptional regulation and the quantitative variations of 
these enzymes. Here, we correlated the level of transcripts and proteins of the two aminopeptidases in 
B-lymphoblastoid cell lines from 44 donors harbouring allelic variants in the intergenic region between 
ERAP1 and ERAP2. We found that the presence of a G instead of an A at SNP rs75862629 in the ERAP2 
gene promoter strongly influences the expression of the two ERAPs with a down-modulation of ERAP2 
coupled with a significant higher expression of ERAP1. We therefore show here for the first time a 
coordinated quantitative regulation of the two ERAP genes, which can be relevant for the setting of 
specific therapeutic approaches.
The ER-resident aminopeptidases ERAP1 and ERAP2 are ubiquitous, zinc-dependent multifunctional enzymes 
involved in immune activation and inflammation1–3, blood pressure regulation4,5 and antigenic peptide repertoire 
shaping6–10]. ERAP1 is a type II integral membrane enzyme, whereas ERAP2 is not. The two aminopeptidases 
share ~49% sequence homology. ERAP1 and ERAP2 genes are both regulated by interferons (IFNs) and Tumour 
Necrosis Factor-α (TNFα)11. Whilst differing for the preferred substrates, they have similar proteolytic activities 
and might even form heterodimers in order to generate optimal peptide repertoires. When overactive, the ERAPs 
can destroy the putative HLA class I ligands by reducing their length below the threshold of 8–10 amino acids. 
Loss of both enzymes is a frequent event significantly associated with the lack of HLA class I surface expres-
sion12–17. While the general rules governing the role of the ERAP genes in antigen processing are well established, 
several studies suggest that the effects on individual HLA class I alleles and/or epitopes may differ18.
The ERAP1 and ERAP2 genes reside in the same cluster located on the long arm of chromosome 5 (5q15), 
where they lie contiguous and oppositely oriented. Both genes are polymorphic with strong linkage disequilib-
rium across the chromosome 5q15 locus and many functional variants appear to primarily affect their enzy-
matic activity. In particular, it has been shown that a splicing variant in the ERAP2 gene (rs2248374)19 leads to 
nonsense-mediated decay (NMD) of the mRNA. Since this variant is maintained by a balanced selection to a 
frequency of approximately 50%, it follows that 25% of the population fails to express the ERAP2 protein20.
GWAS have suggested a role for both ERAP1 and ERAP2 in the onset of several immuno-mediated dis-
eases (IMD), such as ankylosing spondylitis (AS), Behçet’s disease (BD), psoriasis (Ps), inflammatory bowel 
disease (IBD), juvenile idiopathic arthritis (JIA), birdshot chorioretinopathy (BSCR), type I diabetes mellitus 
(T1D) and multiple sclerosis (MS)21–29. In particular, the epistatic interactions observed between ERAP1 and 
HLA-B27 in AS, HLA-Cw6 in Ps and HLA-B51 in BD, strengthen the central role of antigen presentation in the 
so-called “MHC-I-opathy”, although the allelic variants of ERAPs specifically associated with each disease may be 
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different30. In several studies, ERAAP deficient mice resulted in significant changes in the MHC-peptide reper-
toire thus activating CD8+ T lymphocytes and Natural Killer cells31,32. These findings suggest a direct interaction 
of the two ERAP proteins with precursors of HLA class I epitopes, which affect innate and specific immunological 
surveillance.
Overall, an impaired activity and expression, especially of ERAP1, could determine the production of an 
“atypical” peptide repertoire that predisposes to IMDs33 as well as the failure in rejecting tumours and in fighting 
pathogens32,34.
Although most of the studies have been focused on the function of individual SNPs, it must be considered 
that extensive linkage disequilibrium within and around the ERAP genes does exist35,36. Indeed, the combination 
of the ERAP polymorphisms can be termed “allotypes” since they are often co-inherited as complex haplotypes, 
suggesting that this can be the outcome of a selective pressure by pathogens. The SNPs found associated with 
AS and with other IMDs, as well as with cervical cancer and other pathological conditions37–39, probably have a 
synergistic effect with other variations present in the same haplotype40,41. Although there are examples of a direct 
effect of single SNPs on enzymatic activity and substrate binding21,42,43, the data concerning haplotype combina-
tions are conflicting41,44–49. In addition, the functionality of different allotypes may be closely dependent on the 
quality and quantity of the peptide substrates42, as well as on the amount of the enzyme itself. Therefore, in some 
cases, SNPs associated with pathologies may not be causative of the condition themselves, but in linkage disequi-
librium with allelic variants impacting on mRNA transcription, maturation and translation50. This could explain 
why the association between the two ERAP genes and the different IMDs may rely on distinct or even alternative 
polymorphisms harboured by different haplotypes in different ethnic groups51. Furthermore, many risk variants 
in ERAP1 and ERAP2 (rs30187, rs27524, rs27434, rs1363907, rs2549794) have been reported as expression quan-
titative trait loci (eQTL) in most tissues52,53 and their association could derive from quantitative variations and/
or from linkage with other causal SNPs. To date, however, there are no relevant genetic studies in the ERAP1 and 
ERAP2 gene promoters and very little is known about the mechanisms that regulate their expression.
In this study, we have performed a quantitative analysis of ERAP1 and ERAP2 in a panel of (EBV)-transformed 
lymphoblastoid cell lines (B-LCLs) known to express high levels of these aminopeptidases15,54. We found an 
inverse correlation in the expression level of the two aminopeptidases depending on a genetic variant mapping 
in the intergenic region. It is noteworthy that this SNP is in strong LD with an ERAP1 variant found associated 
with several IMDs.
Results
Analysis of ERAP1 and ERAP2 expression in B-LCLs. A panel of forty-four B-LCLs derived from 
Sardinian donors, was analysed for ERAP1 and ERAP2 gene expression. All B-LCLs were genotyped for SNPs 
rs30187 and rs27044 in the ERAP1 gene and rs2248374 in the ERAP2 gene (Fig. 1a).
Figure 1. Cartoon illustrating ERAP1 and ERAP2 genes organization and location of the polymorphisms 
analysed in this study and quantification of ERAP1 and ERAP2 mRNAs in 44 B-LCLs genotyped for SNP 
rs2248374. (a) SNPs rs30187 and rs27044 are functional variants affecting ERAP1 enzymatic activity; SNP 
rs2248374 in ERAP2 gene is a “loss of function” variant, in linkage with the “diagnostic” SNP rs2287988 
located within the coding region. The other polymorphisms indicated in the cartoon have been analysed in 
this study. (b) Heat map diagrams of ERAP1 and ERAP2 expression detected by qRT-PCR analysis in the 44 
B-LCLs analysed (A → RI), (c) Scatter plot of the data points corresponding to the ERAP1 and ERAP2 mRNA 
quantification. Correlation analysis was performed using Pearson’s r.
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The ERAP1 and ERAP2 mRNA number of copies was determined by absolute real time PCR (RT-PCR) and 
then normalized to β-Actin (Fig. S1). As shown in Fig. 1c, regression analysis showed a trend of inverse correla-
tion between the ERAP1 and ERAP2 mRNAs (Pearson r = −0.2524; p = 0.049). Interestingly, among individuals 
heterozygous at rs2248374, 6 out of 24 (Fig. S1) (A → H, except D, hereafter in the text A → H group) showed an 
ERAP2 mRNA copies lower than expected whereas ERAP1 expression was high.
ERAP2 mRNA and protein expression is regulated by other factors besides rs2248374. Western 
blot (Fig. 2a) confirmed the mRNA quantitative analysis. Indeed, G/G individuals at rs2248374 did not express 
ERAP2 due to the introduction of a premature termination codon (PTC) which induces NMD20. However, 
ERAP2 protein was not detectable in the B-LCLs (A → H group) whereas present in all the other samples geno-
typed at rs2248374 as A/A or A/G.
Interestingly, the analysis of the ERAP1 and ERAP2 transcripts showed that the six B-LCLs heterozygous for 
rs2248374 and lacking ERAP2 protein, had a higher ERAP1/ERAP2 mRNA ratio, even above the ratio shown by 
the G/G homozygous in which the ERAP2 mRNA encoded by both haplotypes was degraded by NMD (Fig. 2b).
The presence of the G variant at rs75862629 inversely correlates with ERAP1 and ERAP2 tran-
script levels. To assess whether this variability could be due to cis-regulatory variants, the region between 
the two genes encompassing the TATA-boxes of both promoters was sequenced in three genomic region(Fig. S2). 
Three polymorphisms were identified: rs75862629 (A/G) in the ERAP2 promoter (region named M2), rs2911138 
(C/T) in the M3 region and a “CA” microsatellite in the ERAP1 gene promoter (100 bp upstream the 5′UTR) 
(region named M1). As for the CA repeats, we analysed a total of 400 DNA samples from Sardinia and observed 
a Gaussian distribution of allele frequencies around 32 repeats (data not shown). We therefore arbitrarily named 
as “L” the alleles with a number of repeats equal or higher than 32 and as “S” the alleles with a number of repeats 
lower than 32. The frequency in our panel of 44 B-LCLs was consistent with that of Sardinian population (76% 
“S” and 24% “L”). As for the two SNPs, rs75862629 and rs2911138, their frequency in the Sardinian population 
was similar to that reported for Italy (https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/) with 13% G 
and 77% T, respectively.
Allele distribution of rs2911138 and microsatellite showed no correlation with the level of transcripts of either 
ERAP1 or ERAP2. The G variant at rs75862629 instead, was carried by all those cell lines that, although heterozy-
gous for the functional rs2248374 variant, did not express ERAP2 protein (A → H group, Figs 2a and S3). The 
other cell lines, I, J and V, which were A/A at the functional ERAP2 rs2248374 and which expressed the expected 
amount of ERAP2, have been genotyped as A/G at rs75862629, while the Z cell line (A/A at rs2248374) expressing 
a surprisingly low amount of ERAP2 was indeed G/G at rs75862629. With the exception of the B-LCL, named 
D, which is heterozygous at both SNPs, all the other ERAP2-expressing cell lines, typed as A/G at rs2248374, 
were A/A at rs75862629. Only one subject (O) typed as G/G at rs2248374 was also G/G at rs75862629 (Table S2). 
Therefore, the presence of a G at rs75862629 was consistently correlating with the increased expression of ERAP1 
mRNA (Fig. 3a). The analysis of the ERAP1/ERAP2 mRNAs ratio was then performed by stratifying the samples 
according to the functional ERAP2 rs2248374 genotype. We observed that the G variant at rs75862629 correlated 
with a higher ERAP1/ERAP2 mRNA ratio regardless of the rs2248374 variant (Fig. 3b).
Figure 2. ERAP1 and ERAP2 mRNAs and proteins in B-LCLs according to rs2248374 genotype. (a) 
Representative western blots, out of three, displaying ERAP1 and ERAP2 proteins in 44 B-LCLs. The samples 
were subdivided according to rs2248374 genotype. In the last membrane, besides two A/A and two G/G 
samples and the ctrl (sample Q), an A/G sample (C) not expressing ERAP2 was also loaded as comparison. 
M = Molecular Weight protein Marker; ctrl = Q B-LCL. The upper membranes were incubated first with 
mouse anti-ERAP2 mAb and subsequently with mouse anti-ERAP1 mAb antibody. Full-length gels and blots 
are included in the Supplementary Information file (Fig. S3). (b) Ratio of ERAP1/ERAP2 mRNAs in B-LCLs 
genotyped for rs2248374. Horizontal bars represent the mean ± S.E.M. The Mann-Whitney p value from 
comparison between A/G heterozygous samples expressing and not expressing ERAP2 was <0.0001.
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ERAP2 transcripts degradation is regulated by additional factors besides SNP rs2248374. Next 
we asked whether an increase in the ERAP2 mRNA copy number could directly affect ERAP1 gene expression. 
Thirty-seven B-LCLs were treated for 7 hours with emetine, which blocks translation and NMD. We observed 
that, in the presence of emetine, ERAP1 mRNA did not undergo any significant variation. Unexpectedly, ERAP2 
mRNA expression did increase in all cell lines analysed, even in those B-LCLs typed as A/A at rs2248374 indicat-
ing the presence of uncorrected forms of ERAP2 in addition to that marked by G at rs2248374 (Fig. 4a). Following 
emetine treatment, we observed a higher increase in ERAP2 mRNA in those cells genotyped as A/G or G/G at 
rs75862629, independently from rs2248374 (Fig. 4b). This observation gives support to the hypothesis that the 
G variant at rs75862629, mapping in the region between ERAP1 and ERAP2 genes, might be in linkage with an 
additional polymorphism that impacts the correct “maturation” of the transcript inducing, similarly to G at the 
functional rs2248374, the degradation of ERAP2 mRNA by NMD. The unexpected lack of ERAP2 protein in 
some samples (A → H group, A/G at rs2248374) and Z (A/A at rs2248374) B-LCLs (see Fig. 2a) can be attrib-
uted to G–A/A–G or G–A/G–A rs75862629-rs2248374 haplotype combinations, where the presence of the G at 
rs75862629 has a similar effect to that of the G at rs2248374. As for “D” B-LCL, an A–A/G–G combination can 
therefore be predicted.
The rs75862629 G allele identifies a haplotype correlating with a higher ERAP1 mRNA and a 
lower ERAP2 mRNA expression. To verify whether the haplotype rs75862629-rs2248374 G–A, similarly 
to the haplotype A–G, determines a lower expression of ERAP2, allele-specific quantitative RT-PCR analysis of 
heterozygous B-LCLs under NMD inhibition was carried out. Because of the NMD, the SNP rs2248374 is not 
present in the mature mRNA. Therefore, the expression was monitored using the “diagnostic” SNP rs2287988 
(A/G), which falls within the ERAP2 coding region and presents the variant A in complete linkage with G at 
rs2248374 and viceversa) (20 and our observation). As expected, a lower level of ERAP2 mRNA was expressed by 
the haplotype identified by G at rs2248374 (ratio A–A/A–G > 1). Unexpectedly, the presence of G at rs75862629 
makes the haplotypes ratio G–A/A–G or G–A/G–G close to the unit. Furthermore, NMD inhibition induced an 
increase of the ERAP2 transcript carrying the A–G haplotype of about 8 times, whereas the presence of a G at 
rs75862629 (G–A or G–G) correlates with a lower susceptible to NMD inhibition (Fig. 5a).
These data indicate that, as to the ERAP2 transcripts, the G allele at rs75862629 tags the haplotypes whose 
transcripts are susceptible to NMD. However, the greater effect of the NMD inhibition on the haplotype A–G 
rather than G–A (rs75862629-rs2248374), makes plausible the hypothesis that the G at rs75862629 negatively 
affects ERAP2 transcription by itself. This was strengthened by a further relative allele specific real-time PCR 
analysis in which the cDNAs corresponding to G–A and A–A haplotypes from emetine-treated B-LCLs were 
normalized to the A–G haplotype (Fig. 5b). Cell lines expressing the G–A haplotype (A → H group), produced a 
lower number of copies compared to the B-LCL expressing the A–A combination. These data were further con-
firmed when normalized to the β-Actin endogenous control (data not shown).
Figure 3. Effect of rs75862629 genotype in the expression of ERAP1 and ERAP2. (a) ERAP1 gene expression 
correlates with rs75862629 genotype. The absolute expression of ERAP1 mRNA, as reported in Fig. 2, was 
analysed in the 44 B-LCLs stratified by the rs75862629 genotype. Horizontal bars represent the means ± S.E.M. 
****p value from Mann-Whitney test was <0.0001. (b) Correlation of ERAP1/ERAP2 mRNA ratio with 
rs75862629 in B-LCLs stratified by the rs2248374 genotype. The samples, subdivided according to the 
rs2248374 genotype, were analysed for the ERAP1/ERAP2 ratio depending on the rs75862629 typing. A/G 
and G/G at rs75862629 were pooled together. All but one of individuals typed as G/G at rs2248374 (not 
ERAP2 expressors), were A/A at rs75862629. Horizontal bars represent the means ± S.E.M. p value < 0.01 and 
p < 0.0006 from Mann-Whitney test are indicated by two and three asterisks, respectively.
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Interestingly, the comparison of the haplotypes expressed by the two cohorts reported in Fig. 3a, showed that 
the group of high ERAP1 expressors carrying the G variant at rs75862629, are preferentially within a haplotype 
that includes the variant T at rs30187 (pc = 1.5 × 10−8) (Table 1) although the LD among the SNPs analysed is not 
relevant (Fig. S4).
Discussion
In this study, we have analysed the expression of ERAP1 and ERAP2 in B-LCLs genotyped for rs30187 (K528R) 
and rs27044 (Q730E) SNPs in ERAP1 and rs2248374 in ERAP2 gene. The analysis of the ERAP1 and ERAP2 
mRNA levels in the presence or absence of emetine, a NMD inhibitor, pinpointed the SNP rs75862629, mapping 
in the ERAP2 promoter, as a marker that correlates with a double effect on ERAP2 mRNA, that is, lower tran-
scription and higher degradation. Interestingly, this parallels with a higher ERAP1 transcription suggesting a 
concerted, opposite regulation.
The presence of T at rs30187 (Lys528) has been found associated with AS, non-AS spondyloarthritis, type 
I diabetes, psoriasis, multiple sclerosis, anterior uveitis and enthesitis-related arthritis23. The major allele C 
(Arg528) instead reduces ERAP1 activity and, while protective for AS and psoriasis, is a risk factor for Behçet’s 
disease. It will be interesting to investigate the interplay between the promoter polymorphism rs75862629 that 
controls the quantitative level of ERAP1 and its activity as regulated by rs30187 in different populations and 
different diseases. Of note in Sardinia, the G allele at rs75862629 is part of a haplotype that includes the T allele 
at rs30187 and that characterizes individuals with high ERAP1 expression. This is in agreement with the obser-
vation that the T variant at rs30187 correlates with a higher ERAP1 mRNA transcription and protein expres-
sion, particularly in B-LCLs and monocytes-derived dendritic cells35,36. Other studies have suggested that ERAP1 
expression traits may be under a cis-regulatory control and that rs30187 shows the strongest association with 
cis-regulation tag frequency-derived haplotype frameworks52,55,56. Since the lack of ERAP expression was not 
associated with DNA methylation in the promoter of ERAP1 or ERAP257, our findings suggest that this latter 
phenomenon could be due to the presence of variants that, falling into cis-regulatory elements, would favour the 
hijacking of specific factors towards the ERAP1 rather than ERAP2 transcription. Although our study has been 
limited to few markers and therefore other cis-elements can be responsible of the observed phenomenon, it is 
interesting that the rs75862629 maps within the ERAP2 gene promoter region flanked by putative TATA-box 
sequences thus making plausible that rs75862629 itself may affect gene transcription resulting in a modification 
within the putative transcription factor binding site of IRF-11. In this context, it is remarkable that a constitutively 
inverse mRNA expression pattern was also found for ERAP1 and ERAP2 in melanoma cell lines compared to 
melanocytes57. A further possibility is that ERAP1 grabs transcription factors that control the expression of both 
genes and this results in a poor ERAP2 transcription. A lower production of negative regulators (i.e. non-coding 
RNA), whose genes could overlap with the ERAP2 gene is also conceivable. In this regard, the ERAP2 mRNA, 
regardless of rs2248374 allelic variant and in contrast to ERAP1 mRNA, is particularly influenced by emetine 
Figure 4. ERAP2 but not ERAP1 mRNA is enhanced by NMD inhibition independently from the rs2248374 
genotype. (a) ERAP1 and ERAP2 mRNA copy numbers normalized to 100000 β−Actin copies before and after 
emetine treatment for 7 h in samples stratified according to rs2248374 genotype. (b) ERAPs mRNA fold change 
(emetine/untreated ratio) of the respective mRNAs. The arrows indicate the presence of G at rs75862629. 
p value < 0.0054, p < 0.0008, p < 0.0001 obtained by ratio paired t test are indicated by two, three and four 
asterisks, respectively.
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treatment, suggesting the existence of a higher number of alternatively spliced mRNA isoforms undergoing NMD 
degradation.
These findings provide a new tool to evaluate the functional consequences that a higher expression of ERAP1, 
counterbalanced by a lack of expression of ERAP2, can have in the shaping of the peptidome and on the numer-
ous functions of these enzymes. It must be considered that the ERAPs may influence pathological processes other 
than those strictly involving cell-mediated immunity. Indeed, ERAP1 role in angiogenesis and in the regulation 
of blood pressure arises the possibility that in some IMDs, vascular alterations taking place during inflammation 
Figure 5. ERAP2 haplotype ratio in rs2248374 heterozygous B-LCLs expressing or not the protein. (a) cDNAs 
from B-LCLs heterozygous at rs2248374, were analysed for the expression of ERAP2 haplotypes in the presence 
or absence of emetine treatment. Emetine determined a significant increase in the ERAP2 A–G haplotype in 
those cell lines carrying the A–G/A–A haplotype combination at rs75862629 and rs2248374. In contrast, the 
G–A/A–G haplotype ratio was close to the unit independently from emetine treatment. DNA ctrl represents 
the haplotype ratio measured in a genomic DNA A/G heterozygous at rs2248374 and at the diagnostic SNP 
rs2287988 expected to be ~1.0. Histograms represent the mean ± S.E.M. of duplicate of two independent 
experiments. The average value for allelic ratio among the B-LCLs tested is indicated above each set of bars. 
(b) Relative expression of A allele at rs2248374 in emetine treated B-LCLs. cDNA from emetine-treated B-LCLs, 
heterozygous at rs2248374, were analysed for the expression of ERAP2 haplotypes identified by A variant at 
rs2248374 (rs75862629-rs2248374 A–A and G–A combinations). The values were normalized to the haplotype 
identified by the G variant at rs2248374 (rs75862629-rs2248374 A–G). The presence of a G at rs75862629 
correlates with a reduced expression of ERAP2. Horizontal bars represent the mean ± S.E.M. The p value from 







rs30187 A/G + G/G A/A
A-T-S-C 0.287 0.086 0.363 0.104
A-T-S-T 0.246 0.170 0.275 3.123
G-T-S-T 0.135 0.494 0.000 1.5 × 10−8
A-C-L-T 0.073 0.041 0.085 4.83
A-T-L-C 0.069 0.039 0.079 5.079
A-C-S-C 0.049 0.000 0.067 1.933
A-C-S-T 0.044 0.000 0.061 2.197
A-T-L-T 0.034 0.038 0.033 9.046
G-C-S-C 0.034 0.125 0.000 0.040
A-C-L-C 0.027 0.000 0.037 3.386
Table 1. Frequency of the haplotypes rs75862629-rs2911138-size-rs30187 in the panel of 44 B-LCLs analysed. 
rs75862629 A or G; rs2911138 T or C; size: S (Short, <32 CA repeats) or L (Long, ≥32 CA repeats); rs30187 C 
or T. pc = Bonferroni corrected p value.
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as well as vessel remodelling and stability, can contribute to the pathologies and, in this context, the quantitative 
variations of the ERAP1 expression can play a relevant role58.
In conclusion, we demonstrated the existence of a regulatory intergenic region marked by the SNP rs75862629 
that balances the level of the two ERAP genes. Overall, a deeper knowledge of the possible consequences of ERAPs 
quantitative variations, particularly of ERAP1, and of factors controlling their expression, may well be fundamen-
tal to the design of novel and specific therapeutic approaches in different pathologies.
Methods
Ethics. Peripheral Blood Mononuclear Cells (PBMC) were collected from forty-four Sardinian donors 
recruited in the Department of Medical Sciences, University of Cagliari, Italy. Informed consent was obtained by 
all subjects and the study was approved by the local ethics committee (365/09/CE, University Hospital, Cagliari, 
Italy). All experiments were performed in accordance with relevant guidelines and regulations.
B-Lymphoblastoid cell line generation and culture. PBMC were isolated from 30 ml of freshly drawn 
blood by Ficoll density-gradient centrifugation (StemCell Technologies). B-lymphoblastoid cell lines (B-LCLs) 
were established from Epstein-Barr virus (EBV) transformed B lymphocytes according to the standard pro-
tocol59, and grown in an atmosphere with 5% CO2 at 37 °C in RPMI 1640 medium supplemented with 10% 
heat-inactivated fetal bovine serum, penicillin (100 units/ml), streptomycin (100 μg/ml) and amphotericin B 
(Invitrogen). B-LCLs were cultured at 5 × 105/ml. For the inhibition of Nonsense Mediated Decay (NMD), cells 
were transferred to a new flask and kept in culture for 7 h in the presence or absence of emetine (Sigma) at con-
centration of 100 μg/ml.
Genotyping. Genomic DNA was obtained from B-LCLs or from EDTA-treated peripheral blood samples 
using QIAamp DNA Blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. SNPs 
genotyping was performed by quantitative Real-Time Polymerase Chain reaction (qRT-PCR) with function-
ally tested TaqMan Allelic Discrimination Assay (rs30187: C_3056885_10; rs27044: C_3956870_10; rs2248374: 
C_25649529_10; rs2287988: C_25649516_10; 7300 real-time PCR system, Applied Biosystems). The analysis of 
the genomic regions reported as M1, M2 and M3 (Fig. S2) and the typing of SNPs rs75862629 and rs2911138 
were determined by direct sequencing. Briefly, 3 amplicons (1 for each region) were amplified from 100 ng of 
genomic DNA in a final volume of 30 μl containing: 0.5 μM of each primer (Table S1); 1x PCR Buffer; 200 μM 
of dNTP mix and 0.8 U of “High Fidelity DNA Polymerase” (New England BioLabs). Cycling conditions were 
as following: 10 s at 98 °C, 20 s at 57 °C, and 30 s at 72 °C for 35 cycles; followed by a final step of 10 min at 72 °C. 
PCR products were checked by agarose gel electrophoresis using GelGreen nucleic acid staining (10,000x in 
water, Biotium). Approximately 40 ng of the purified product underwent sequencing on an ABI 3730xl capillary 
sequencer (Applied Biosystems) and analysis by Bioedit software.
The number of CA repeats (hereinafter named as “size”) in the promoter region of ERAP1 gene was deter-
mined by fragment length analysis. Briefly, the microsatellite region was amplified by PCR with fluorescent 
(6-FAM) −5′-end labelled primers (Table S1). PCR products were size-separated and analysed on Applied 
Biosystems 3730 automated sequencer equipped with GENESCAN software (Applied Biosystems). A standard 
size of repeats was obtained by cloning the fragment from U937 cells (22 CA).
Gene expression analysis. Total RNA from B-LCLs was extracted using Trizol Reagent (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. RNA was quantified by a Nanodrop spectrophotom-
eter ND-1000 (Thermo Scientific) and its quality was assessed by 1% agarose/Tris–Acetate–EDTA (TAE) gel 
electrophoresis. 1 μg of RNA underwent reverse transcription reaction using High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems).
ERAP1, ERAP2 and β-Actin mRNA absolute quantification was performed by qRT-PCR using the standard 
curve method. RT-qPCR was performed with gene specific primer sets (Table S2) in a singleplex, using the SYBR 
PrimeScript RT-PCR kit and an Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems; Thermo 
Fisher Scientific, Inc.). qPCR was performed in 20 µl containing 10 µl of SYBR Green PCR Master mix (Roche 
Diagnostics), 1 µl cDNA, 100 µM of forward and reverse primers for 45 cycles at 95 °C for 30 sec and 60 °C for 
1 min after an initial step at 95 °C for 10′. A dissociation step was included in all reactions to confirm single spe-
cific PCR product amplification and to define the Tm for each amplicon. Genomic DNA, reverse-transcription 
and positive PCRs were analysed to control for genomic DNA contamination, reverse transcription efficiency 
and polymerase chain reaction, respectively. For absolute quantification, absolute transcript copy numbers for 
each gene and replicate were calculated with the ABI 7500 system SDS software version 1.4 (Applied Biosystems). 
Absolute quantification is expressed as mean number of copies (nc) from six amplification values (duplicate of at 
least three independent experiments) with standard deviation. For absolute quantification with normalization, 
absolute transcript copy numbers were related to 100000 copy numbers of β-Actin endogenous control.
Analysis of allele-specific gene expression. B-LCLs heterozygous at SNP rs2248374 were treated with 
100 μg/ml of emetine (Sigma) for 7 hours to inhibit NMD60. Total RNA was extracted, treated with DNase accord-
ing to the manufacturer’s instructions (RQ1 RNase-Free DNase, Promega) and used to generate cDNA as already 
described. Haplotype-specific ERAP2 cDNA was quantified in triplicate using an allele-discriminating TaqMan 
genotyping assay for the rs2287988 coding diagnostic SNP20. Briefly, we generated a standard curve consisting of 
serial dilutions of DNA samples homozygous for A or for G allele. We used a heterozygous genomic DNA sample 
to validate the regression equation, in which a mean allelic ratio of 1.0 was expected.
Relative quantification of rs75862629-rs2248374 G–A and A–A haplotypes after emetine treatment was per-
formed using the TaqMan genotyping assay for the rs2287988 coding diagnostic SNP. The expression level of 
mRNAs is indicated as ratio of the targets normalized to the A-G haplotype using the 2−ΔΔCt method, as ratios 
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of fold change relative to the calibrator. The 2−ΔΔCt method assumes that the amplification efficiency of the 
reaction is ideal and constant for each sample.
Western blot analysis. Approximately 3 × 106 cells were harvested, washed twice in 1x PBS and lysed for 
30 min on ice in 30 μl of 1% NP40 protein lysis buffer containing 100 U/ml of phenylmethylsulfonyl fluoride 
(PMSF), 1 μg/ml of aprotinin and 0.5% sodium deoxycholate proteinase inhibitors. Proteins were obtained from 
the cell lysates by centrifugation at 16363 g for 15 min at 4 °C, and their concentrations determined using the 
Biorad protein assay kit (Biorad, Hercules, CA) with bovine serum albumin (BSA) used as standard. 40 μg of 
protein extract for each sample were separated on a 4–12% NuPage Bis-Tris gel (Invitrogen) at 125 V for 100 min 
in NuPage MES SDS Running Buffer (Invitrogen), and transferred to nitrocellulose membranes. The mem-
branes were incubated ON with mouse anti-ERAP1 mAb antibody (clone B-10, sc-271823 SantaCruz), mouse 
anti-ERAP2 mAb (clone 3F5, MAB 3830 R&D Systems) and mouse anti-β-Actin mAb (clone C4, sc-477778 
SantaCruz). The membranes were washed twice in TBST, incubated with horseradish peroxidase–conjugated 
secondary Ab (Jackson Immunoresearch Laboratories, Inc. West Grove, PA) and revealed by ECL Western blot-
ting detection system (Amersham). The proteins were visualized by ChemiDoc XRS+ System (Biorad, California, 
USA).
Statistics. In the scatter plots the mean ± standard error of the mean (SEM) are indicated. Pearson’s test 
(one tailed) was employed for the correlation analysis of ERAP1 and ERAP2 transcripts. For comparison of two 
groups, two tailed Mann–Whitney U-test or paired t test were used. Statistical analyses were performed using 
GraphPad Prism 5 software (GraphPad, San Diego, CA, USA). Haploview version 3.2 (http://www.broad.mit.edu/
mpg/haploview/) was used to analyse the patterns of haplotype blocks (chi square p values). P values underwent 
Bonferroni correction for multiple comparisons.
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